

CORPORATE PROFILE


Dthera Sciences (OTCQB:DTHR), based in San Diego, Calif., is a digital therapeutics company focused on developing innovative quality of life therapies for the elderly and those suffering from cognitive decline. The Company's lead product, ReminX, is an artificial-intelligence-powered consumer health product designed to deliver reminiscence therapy digitally to individuals suffering from dementia from Alzheimer's disease and other neurodegenerative conditions, as well as for seniors experiencing social isolation. The company plans to launch ReminX commercially in the second quarter of 2018.

7310 Miramar Road Suite 350
San Diego CA, 92126
Phone: Tel: 858-215-6360
<http://dthera.com>
IR@dthera.com

CORE IR
377 Oak Street
Garden City, NY 11530
Tel: 516-222-2560
www.coreir.com

STOCK PERFORMANCE

Symbol	DTHR
Exchange	OTCQB
Market Cap.	21.91m
52 Week Range	0.4353 - 30.00
Close	0.4353
Volume	0
Shares Outstanding	50,343,367
As of Jun 7, 2018 11:27 am	



MANAGEMENT TEAM

Edward Cox - CEO

Dave Keene - CTO

BOARD OF DIRECTORS

Michael R. Feldschuh - Director

James A. Lombard - Director

Martin S. Wolpoff - Director

Edward S. Feuer - Director

Bernhard Saxe - Director

Jonathan Feldschuh - Chief Scientific Officer

RECENT HEADLINES

[May 10, 2018 - Form CT ORDER](#)

[May 3, 2018 - ReminX Dementia Paper Accepted at International Academic Conference](#)

[Apr 16, 2018 - Dthera Sciences Appoints Steve R. Martin to Board of Directors](#)

[Apr 3, 2018 - Dthera Sciences Announces 2017 Financial Results and Provides Business Update](#)

[Mar 23, 2018 - Dthera Sciences Commends the Work of the Alzheimer's Association to Raise Awareness of the High Cost of the Disease on Healthcare System and Caregivers](#)

PAST EVENTS

Dec 14, 2016 - Dthera Sciences Investor Presentation Live Webcast